ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO1837

Vitamin D Deficiency and Outcome of IgA Nephropathy in North Indian Patients

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Farooqui, Naba, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Bagchi, Soumita, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Subbiah, Arunkumar, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Chaturvedi, Pradeep, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Sati, Hem, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Bhowmik, Dipankar M., All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Agarwal, Sanjay K., All India Institute of Medical Sciences, New Delhi, Delhi, India
Background

Vitamin D has been shown to be beneficial in reducing proteinuria in patients with chronic kidney disease (CKD). IgA Nephropathy (IgAN) is one of the leading causes of CKD in India and worldwide. Asians, especially Indians develop more severe IgAN. We conducted this study to evaluate 25-hydroxy vitamin D (25(OH)D) level as a prognostic marker for disease progression and outcomes in a cohort of Indian patients with IgAN.

Methods

In this retrospective cohort study, demographic and clinical data of Indian adult patients with biopsy proven IgAN, diagnosed between 2015 and 2019, was obtained. Patients with a minimum follow-up of 6 months were included for analysis. A 25-(OH)-vitamin D assay was performed on serum samples collected at the time of kidney biopsy. 25-(OH) D levels <10 ng/mL were considered as deficient.

Results

Of the 105 patients included in the study, 69.5% were males. The mean age was 34.0±10.6 yrs. The mean baseline creatinine and 24 hr proteinuria was 1.37±0.51mg/dL and 3.12±2.45 g/day, respectively. The mean baseline vitamin D levels were 15.88±11.85 ng/mL. 39% patients were 25(OH)D deficient. The median duration of follow up was 23.5 months (range: 6 – 56 mon). Eleven patients (10.5%) progressed to end stage renal disease (ESRD) during follow-up. Vitamin D deficiency was not significantly associated with progression to ESRD (p=0.61) or proteinuria remission (0.83).Risk for ESRD was reduced in patients with lower baseline creatinine levels (p=0.00) and patients on ACE inhibitors (p=0.03). Remission of proteinuria was more common in patients with lower baseline creatinine levels (p=0.006) and normotensive patients (p=0.03). Baseline creatinine (HR = 14.40; 95% CI, 1.02 – 202.15), 24 hr proteinuria (HR = 0.03; 95% CI, 0.00–0.85) and disease remission (HR = 0.01; 95% CI, 0.00–0.32) were predictors of risk for ESRD.

Conclusion

Vitamin D deficiency is common in Indian patients with IgAN. Baseline vitamin D deficiency did not affect outcomes of IgAN.

Funding

  • Government Support - Non-U.S.